<DOC>
	<DOCNO>NCT01692782</DOCNO>
	<brief_summary>A Phase 2 study SEP-225289 adult attention deficit hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Adult Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>This Phase 2 , randomize , double-blind , parallel-group , multicenter , outpatient study evaluate efficacy safety SEP 225289 adult ADHD use 2 oral dosage ( 4 8 mg SEP 225289 daily [ QD ] ) versus placebo 4 week treatment period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subject meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ; Text Revision ( DSMIVTR ) criteria primary diagnosis ADHD ( inattentive , hyperactive , combine subtype ) establish comprehensive psychiatric evaluation review DSMIVTR criterion . Diagnosis confirm Conners ' Adult ADHD Diagnostic Interview ( CAADID ) Part 2 . Subject currently take medication ( stimulant nonstimulant ) control ADHD symptom ADHD RSIV score ≥ 22 screening . Subject currently take medication purpose control ADHD symptom ADHD RSIV score ≥ 26 screening . Subject CGIS score ≥ 4 screening . Subject lifetime history treatment least one medication ADHD ( stimulant nonstimulant ) . Subjects may either medicate unmedicated ADHD time screen ( ADHD medication must wash screen ) . Subject negative breath alcohol test negative urine drug screen ( UDS ) illicit drug screening , unless false positive suspect , case UDS repeat . If subject positive drug screen ADHD medication ( ie , methylphenidate amphetamine ) screening ; subject must negative UDS washout period least 3 day prior baseline . Subject male nonpregnant , nonlactating female . Female subject must negative serum pregnancy test screening ; woman postmenopausal ( define least 12 month spontaneous amenorrhea ) undergone hysterectomy bilateral oophorectomy exempt pregnancy test . Female subject childbearing potential male subject female partner childbearing potential must agree use effective medically acceptable form birth control throughout study period one month ( 30 day ) study completion . Medically acceptable effective contraceptive include abstinence , prescription hormonal contraceptive ( oral , patch , vaginal ring , implant , injection ) , diaphragm spermicide , intrauterine device ( IUD ) , condom spermicide , surgical sterilization , vasectomy . For male subject adequate contraception define abstinence continuous use 2 barrier method contraception ( eg , spermicidal condom ) . Subject 18 55 year old , inclusive , time informed consent . 11 . Subject read well enough understand informed consent form subject material . Subject DSMIVTR diagnosis ADHD otherwise specify . Subject receive adequate benefit current ADHD medication opinion investigator . Subject Axis I disorder ADHD primary focus treatment time 12 month prior screen . Subject past history , current presentation consistent , bipolar disorder ( include bipolar I , bipolar II , bipolar otherwise specify [ NOS ] ) , schizophrenia , schizoaffective disorder , psychotic disorder . Subject history drug dependence substance abuse ( exclude nicotine caffeine ) within 12 month prior screen , define DSMIVTR criterion . Subject current Axis II disorder per DSMIVTR criterion . Subject history epilepsy , seizure ( except childhood febrile seizure ) , unexplained syncope unexplained blackout ( except single incident ) , head trauma loss consciousness last 5 minute . Subject currently active medical condition ( ADHD ) , opinion investigator , could interfere ability subject participate study . Subject currently take antidepressant medication ( eg , bupropion , selective serotonin reuptake inhibitor [ SSRI ] / serotonin norepinephrine reuptake inhibitor [ SNRI ] , monoamine oxidase [ MAO ] blocker , tricyclic , etc ) St. John 's Wort . Subject currently take take within previous 6 month anticonvulsant medication ( eg , phenytoin , carbamazepine , lamotrigine , valproic acid , etc ) ; antipsychotic medication ; lithium ( lithium preparation formulation ) . Subject currently take alpha2 adrenergic receptor agonist ( include clonidine guanfacine ) . Subject Body Mass Index ( BMI ) less 18 great 35 kg/m2 ( refer Appendix V ) Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) CSSRS assessment screening ( past month ) . Subjects answer `` yes '' question must refer Investigator followup evaluation . Subject attempt suicide within 2 year prior screen period . Subject history positive test Hepatitis B surface antigen Hepatitis C antibody . Note : Subjects history positive test Hepatitis B surface antigen Hepatitis C antibody may enrol study liver function test result screen within normal range . Subject know tested positive human immunodeficiency virus ( HIV ) . Subject clinically significant abnormality screen evaluation include physical examination , vital sign , ECG , laboratory test investigator consultation medical monitor considers inappropriate allow participation study . The subject 's screening ECG show correct QT interval use Fridericia 's formula ( QTcF ) ≥ 450 msec male subject ≥ 470 msec female subject . The subject 's screening hematology result show alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value ≥ 2 time upper limit normal ( ULN ) , blood urea nitrogen ( BUN ) value ≥ 1.5 time ULN reference lab . Subject currently participate participate clinical trial within last 180 day participate 2 clinical trial within past year . This include study use marketed compound device . Subject high risk noncompliance investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Attention deficit hyperactivity disorder</keyword>
</DOC>